The 3rd Chronic Kidney Disease Drug Development (CKD3) Summit is the industry’s definitive forum dedicated to developing more innovative, targeted and clinically successful drugs to more meaningfully address chronic kidney disease is back!
Gathering cross-industry experts from nephrology, cardiology, and endocrinology to analyze and overcome challenges in diabetic kidney and rare glomerular disease drug development, CKD3 is the must-attend forum for focused discussion and actionable insights to further CKD drug development.
From foundational science for target identification through to patient recruitment and costings of approved drugs in orphan indications, hear from over 30 speakers and gain candid insights on the latest results to inform your pipeline from concept to clinical trials.
"CKD3 is a unique event in the nephrology space. Its focus on all aspects of successful and patient-centered clinical trials of CKD-related therapy fills an important gap in getting more of these therapies to market. I will definitely attend next year."
National Kidney Foundation
“The conference enabled me the opportunity to learn about the latest developments regarding a broad range of topics on CKD. More importantly, I was surrounded by an engaging and knowledgeable international audience that were willing to continue the dialogue after they returned to their day jobs."
"This conference incorporates an overview of current drug discovery landscape in CKD but is also designed to shed light on the factors important to patients and regulatory bodies sending an overarching message on the importance of teamwork between various stakeholders to bring new therapies to CKD patients."
"The Hansonwade events really provide the opportunity to meet and connect with individuals that are interested in the same areas you are."
Expert Speakers for 2020 Include
Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics
University of Michigan
Senior Medical Director & Global Clinical Development Lead - Empagliflozin in CKD
Head of Clinical Renal, Early CVRM